The Center-Val de Loire region, through its regional fund “Centre-Val de Loire Investissement”, has just invested 500,000 euros in the startup Lovaltech, an innovative company founded in 2022 that develops protein vaccines for nasal administration. The funding is part of a €6.8 million fundraising effort to “accelerate phase 1 and 2 clinical trials of the first nasal COVID-19 vaccine” from Lovaltech.

This Lovaltech vaccine could be a new step forward in the fight against COVID-19. thanks to simplified and non-invasive administration through the nose and storage at a positive temperature, facilitating its distribution. This next-generation, recombinant protein-based, unadjuvanted vaccine is designed to provide optimal protection, preventing both infection and infectivity, against all current and future strains or variants of SARS-CoV-2, with the goal of achieving universal immunity. ” announces a startup that plans to commercialize its vaccine in 2026.

This investment demonstrates the Centre-Val de Loire region’s desire to support innovative companies and the development of new biotechnology solutions. ” We hope that this new investment will be the catalyst that persuades more researchers to launch innovative projects in our territory. “, explains the Region. The state, for its part, is providing 5.3 million euros in funding, supplemented by Da Vinci Labs (a well-known startup incubator well known in Touraine, which Magcenter spoke about) with 600,000 euros, as well as other private investors.